Patents by Inventor Mary Leddy
Mary Leddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210230260Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: ApplicationFiled: September 9, 2020Publication date: July 29, 2021Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Publication number: 20180362629Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and caninized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: August 31, 2018Publication date: December 20, 2018Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Patent number: 10125192Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: GrantFiled: July 13, 2015Date of Patent: November 13, 2018Assignee: ZOETIS BELGIUM S.A.Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Patent number: 10093725Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: GrantFiled: July 14, 2015Date of Patent: October 9, 2018Assignee: ZOETIS BELGIUM S.A.Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20180162933Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: ApplicationFiled: December 5, 2017Publication date: June 14, 2018Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Publication number: 20170166633Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: ApplicationFiled: December 23, 2016Publication date: June 15, 2017Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Patent number: 9605069Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: GrantFiled: January 7, 2015Date of Patent: March 28, 2017Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Patent number: 9505829Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: GrantFiled: August 19, 2011Date of Patent: November 29, 2016Assignee: ZOETIS BELGIUM S.A.Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20160264656Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: July 14, 2015Publication date: September 15, 2016Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20160002324Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: July 13, 2015Publication date: January 7, 2016Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20150183871Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: ApplicationFiled: January 7, 2015Publication date: July 2, 2015Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Patent number: 8962803Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: GrantFiled: February 20, 2009Date of Patent: February 24, 2015Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Publication number: 20130330348Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: August 19, 2011Publication date: December 12, 2013Applicant: ABBOTT LABORATORIESInventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20100028340Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: ApplicationFiled: February 20, 2009Publication date: February 4, 2010Applicants: Abbott GmbH & Co. KG, Abbott LaboratoriesInventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell